Press Releases

EndoBarrier® Therapy Receives OPS Codes in Germany and Switzerland

LEXINGTON, Massachusetts & SYDNEY, Australia – 1 October 2013 – GI Dynamics, Inc. (ASX: GID) announced today that the German Institute of Medical Documentation and Information (DMDI) has designated preliminary OPS codes (Operationen- and Prozedurenschlussel) to EndoBarrier® Therapy which is...

read more

Clinical Research Findings Presented at European Diabetes Meeting Reinforce Efficacy of EndoBarrier® Therapy in Treatment of Type 2 Diabetes

Data from two patient registries in commercialized markets, clinical research and a meta-analysis of 13 clinical studies highlighted in four presentations at EASD LEXINGTON, Mass. & BARCELONA, Spain – 25 September 2013 – GI Dynamics, Inc. (ASX: GID) announced today that EndoBarrier® Therapy...

read more

GI Dynamics Reports on Recent EndoBarrier® Therapy Clinical Highlights and Activities

LEXINGTON, Mass. and SYDNEY – 17 September 2013 – GI Dynamics, Inc. (ASX: GID) today announced recent clinical research presentations and peer-reviewed publications about EndoBarrier® Therapy and an update from the successful, inaugural meeting of its European Union Advisory Board. “The...

read more

GI Dynamics, Inc. Provides Update on Progress of the ENDO Trial

LEXINGTON, Massachusetts & SYDNEY – 12 September 2013 – GI Dynamics, Inc. (ASX: GID) today announced an update on the progress of the ENDO Trial, its U.S. multi-center, pivotal clinical trial of EndoBarrier® for the treatment of patients who have uncontrolled type 2 diabetes and obesity. To...

read more

Association of British Clinical Diabetologists Funds and Initiates National Health Service Supported Study of EndoBarrier® Therapy in the United Kingdom

REVISE-Diabesity to Evaluate EndoBarrier Therapy in Patients with Uncontrolled Type 2 Diabetes and Obesity  LEXINGTON, Massachusetts & SYDNEY – 10 September 2013 – GI Dynamics, Inc. (ASX: GID) today announced that the Association of British Clinical Diabetologists (ABCD) has initiated an open...

read more

GI Dynamics to Present at Canaccord Genuity 33rd Annual Growth Conference

LEXINGTON, Massachusetts and SYDNEY – 8 August 2013 – GI Dynamics, Inc. (ASX: GID), announced today that management will present at the Canaccord Genuity 33rd Annual Growth Conference to be held August 14-15, 2013, at the InterContinental Hotel in Boston. Stuart A. Randle, president and chief...

read more

GI Dynamics, Inc. Announces Completion of A$57.5 Million Private Placement And Launch of Share Purchase Plan

Lexington, Mass., United States and Sydney, Australia – 3 July 2013 AEST – GI Dynamics, Inc. (ASX: GID) (“GI Dynamics” or the “Company”) is pleased to announce that it has received commitments for an oversubscribed private placement of 108.5 million fully paid CHESS Depositary Interests (CDIs) at...

read more

GI Dynamics, Inc. Appoints Distributor for the Middle East

LEXINGTON, Massachusetts and SYDNEY, Australia – 26 June 2013 – GI Dynamics, Inc. (ASX: GID) today announced that it has appointed Al-Nozha Medical Est., based in Jeddah, Saudi Arabia, as the distributor of EndoBarrier®, GI Dynamics’ proprietary treatment for type 2 diabetes and/or obesity, in...

read more

French Government Approves Two-Year Clinical Utility Study of EndoBarrier® Therapy

 ENDOMETAB will enroll 174 subjects at multiple sites throughout France LEXINGTON, Massachusetts & SYDNEY – 19 June 2013 – GI Dynamics, Inc. (ASX: GID) today announced that the French Ministry of Social Affairs and Health has approved a large, randomized, multi-center clinical utility study of...

read more

GI Dynamics Announces New Commercial Centres Offering EndoBarrier® Therapy in the European Union

New Centres in Spain, Switzerland and Germany Bring Total Number to 37 Globally LEXINGTON, Massachusetts and SYDNEY, Australia – 18 June 2013 – GI Dynamics, Inc. (ASX: GID) today announced that five prestigious new centres in Europe have begun offering EndoBarrier® Therapy, the Company’s...

read more
Page 10 of 18« First...89101112...Last »